TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Austar Lifesciences Ltd. ( (HK:6118) ) has issued an announcement.
Austar Lifesciences Ltd. announced its annual results for the year ended December 31, 2024, reporting a turnaround with a profit of RMB 13.6 million from continuing operations, compared to a loss in the previous year. The company’s revenue decreased to RMB 1.5 billion, but improvements in gross profit margin and reductions in selling, marketing, and administrative expenses contributed to the positive outcome. This financial performance indicates a strategic recovery, potentially enhancing the company’s market position and offering positive implications for stakeholders.
More about Austar Lifesciences Ltd.
Austar Lifesciences Ltd. operates in the life sciences industry, focusing on providing solutions and products related to pharmaceuticals and biotechnology. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: 49.12%
Average Trading Volume: 140,019
Technical Sentiment Signal: Buy
Current Market Cap: HK$435.7M
See more insights into 6118 stock on TipRanks’ Stock Analysis page.